CompletedPhase 2NCT00404092

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Cologne
Principal Investigator
Oliver A. Cornely, MD
Klinikum der Universität zu Köln
Intervention
caspofungin(drug)
Enrollment
46 enrolled
Eligibility
18 years · All sexes
Timeline
20062009

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00404092 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials